Alendronate Sodium Tablet
Product Images NDC 76282-681

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 76282-681). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

Chemical structure of Alendronate sodium showing its molecular formula with phosphonate groups, hydroxyl groups, and an aminoalkyl side chain, including the sodium ion and three water molecules of hydration.*

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

A line graph depicting the cumulative incidence of hip fractures over 36 months in patients with radiographic vertebral fracture at baseline. The graph compares placebo and alendronate sodium, showing a higher cumulative incidence with placebo than with alendronate sodium over time.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

A bar chart showing the mean percentage increase in bone mineral density (BMD) relative to placebo with Alendronate Sodium 10 mg/day at three years in postmenopausal women. The chart compares results among U.S. and multinational study groups across three bone sites: lumbar spine, femoral neck, and trochanter.*

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

A paired line graph depicting osteoporosis treatment studies in postmenopausal women. The graphs compare the effect of Alendronate Sodium 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline over 36 months in a US study and a multinational study. Both graphs show mean percent change in BMD on the y-axis and time in months on the x-axis, illustrating increased BMD with Alendronate Sodium treatment compared to placebo.*

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

A dual bar chart titled 'Osteoporosis Prevention Studies in Postmenopausal Women' showing mean percent change in Bone Mineral Density (BMD) from baseline over 2-year and 3-year studies. The charts compare BMD changes at lumbar spine, femoral neck, trochanter, and total body between Alendronate Sodium 5mg/day and placebo groups, with Alendronate groups showing positive BMD changes and placebo groups showing negative changes.*

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

A bar chart titled 'Studies in Glucocorticoid - Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year.' It compares the mean percentage increase in bone mineral density (BMD), relative to placebo, at three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter, for two groups labeled U.S. and Multinational. The chart includes error bars representing standard error.*

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

A line graph titled 'Studies in Paget's Disease of Bone Effect on Serum Alkaline Phosphatase of Alendronate Sodium 40 mg/day Versus Placebo or Etidronate 400 mg/day.' It shows mean percent change from baseline in serum alkaline phosphatase over 6 months for four groups: placebo, Etidronate 400 mg/day, Alendronate Sodium 40 mg/day multinational study, and Alendronate Sodium 40 mg/day U.S. study. Data points include sample sizes (N) for each group.*

FDA Label Image

35mg-1x4s-pack-carton (1203dd0c 809a 4409 B948 B5e816b8a63a 08)

Carton label for ALENDRONATE SODIUM 35 mg oral tablets by Exelan Pharmaceuticals Inc. The label states it contains one blister of 4 tablets, with instructions for dispensing and tablet removal. The label includes directions, storage conditions, manufacturer details, lot and expiration information, and a barcode.*

FDA Label Image

70mg-1x4s-pack-carton (1203dd0c 809a 4409 B948 B5e816b8a63a 09)

Packaging label for ALENDRONATE SODIUM 70 mg tablets, USP, manufactured and labeled by Exelan Pharmaceuticals Inc. The label indicates a once-weekly oral tablet dosage form, provided in a blister pack of 4 tablets. It includes dosage information, storage instructions, removal instructions for tablets from the blister, and a barcode. The label also contains a QR code and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.